Cat. No.: HY-18732

L-NMMA

(Synonyms: Tilarginine; Methylarginine)

11 Cited Publications

Customer Review

Based on 11 publication(s) in Google Scholar

L-NMMA (Tilarginine) is a non-selective and competitive inhibitor of nitric oxide synthase. L-NMMA inhibits three subtypes, namely nNOS, eNOS, and iNOS, and reduces NO production. L-NMMA alleviates mechanical allodynia, thermal hyperalgesia, and choroidal fibrosis. L-NMMA is applicable to research related to nociception, bone cancer pain, and myopia.

For research use only. We do not sell to patients.

Purity: 99.43%
CAS No.: 17035-90-4
Formula: C₇H₁₆N₄O₂
Molecular Weight:188.23

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

L-NMMA Chemical Structure

CAS No.: 17035-90-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vivo
- Clinical Trial
Chemical Information
Publications (11)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All NO Synthase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
BV-2	IC₅₀	13.2 μM Compound: L-NMMA	Inhibition of LPS-induced NO production in mouse BV2 cells Inhibition of LPS-induced NO production in mouse BV2 cells	[PMID: 18178435]
BV-2	IC₅₀	16.8 μM Compound: L-NMMA	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess reagent method Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess reagent method	[PMID: 19900811]
BV-2	IC₅₀	17.08 μM Compound: NMMA	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of lipopolysaccharide induced NO production Antiinflammatory activity in mouse BV2 cells assessed as inhibition of lipopolysaccharide induced NO production	[PMID: 21420296]
BV-2	IC₅₀	15.41 μM Compound: L-NMMA	Anti-neuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production pretreated for 30 mins before LPS-stimulation measured after 24 hrs by Griess reaction Anti-neuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production pretreated for 30 mins before LPS-stimulation measured after 24 hrs by Griess reaction	[PMID: 21936523]
BV-2	IC₅₀	18.25 μM Compound: NMMA	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production treated 30 mins before LPS stimulation measured after 24 hrs by Griess reaction Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production treated 30 mins before LPS stimulation measured after 24 hrs by Griess reaction	[PMID: 22951040]
BV-2	IC₅₀	16.27 μM Compound: NMMA	Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method	[PMID: 23149227]
BV-2	IC₅₀	14.29 μM Compound: L-NMMA	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of nitric oxide production treated 30 mins before LPS challenge measured after 24 hrs by Griess reagent method Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of nitric oxide production treated 30 mins before LPS challenge measured after 24 hrs by Griess reagent method	[PMID: 23411079]
BV-2	IC₅₀	16.32 μM Compound: L-NMMA	Anti-neuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 10 mins by Griess assay relative to control Anti-neuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 10 mins by Griess assay relative to control	[PMID: 23462643]
BV-2	IC₅₀	18.26 μM Compound: NMMA	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 23707257]
BV-2	IC₅₀	16.8 μM Compound: L-NMMA	Antiinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 30 mins prior to LPS-challenge measured after 24 hrs by Griess assay Antiinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 30 mins prior to LPS-challenge measured after 24 hrs by Griess assay	[PMID: 23815260]
BV-2	IC₅₀	24.3 μM Compound: L-NMMA	Antineuroinflammatory activity against human BV2 cells assessed as inhibition of LPS-induced NO production treated with compound 30 mins and challenged with LPS for 24 hrs Antineuroinflammatory activity against human BV2 cells assessed as inhibition of LPS-induced NO production treated with compound 30 mins and challenged with LPS for 24 hrs	[PMID: 25098650]
BV-2	IC₅₀	18.3 μM Compound: NMMA	Inhibition of LPS-induced nitric oxide production in mouse BV2 cells treated for 30 mins prior to LPS stimulation for 24 hrs by Griess assay Inhibition of LPS-induced nitric oxide production in mouse BV2 cells treated for 30 mins prior to LPS stimulation for 24 hrs by Griess assay	[PMID: 25466198]
BV-2	IC₅₀	24.8 μM Compound: L-NMMA	Antiinflammatory activity against LPS-stimulated mouse BV2 cells assessed as inhibition of nitric oxide production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess assay Antiinflammatory activity against LPS-stimulated mouse BV2 cells assessed as inhibition of nitric oxide production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess assay	[PMID: 25894905]
BV-2	IC₅₀	14.4 μM Compound: L-NMMA	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated nitric oxide production preincubated for 4 hrs followed by LPS challenge measured after 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated nitric oxide production preincubated for 4 hrs followed by LPS challenge measured after 24 hrs by Griess assay	[PMID: 26126961]
BV-2	IC₅₀	20.53 μM Compound: L-NMMA	Anti-neuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay Anti-neuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay	[PMID: 26706168]
BV-2	IC₅₀	16.27 μM Compound: NMMA	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 26774654]
BV-2	IC₅₀	24.8 μM Compound: L-NMMA	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay	[PMID: 26812172]
BV-2	IC₅₀	20.78 μM Compound: L-NMMA	Anti-neuroinflammatory activity in LPS-activated mouse BV2 cells assessed as inhibition of NO production after 24 hrs by Griess assay Anti-neuroinflammatory activity in LPS-activated mouse BV2 cells assessed as inhibition of NO production after 24 hrs by Griess assay	[PMID: 26988298]
BV-2	IC₅₀	14.4 μM Compound: L-NMMA	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 4 hrs followed by LPS stimulation for 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 4 hrs followed by LPS stimulation for 24 hrs by Griess assay	[PMID: 27140807]
BV-2	IC₅₀	39.28 μM Compound: L-NMMA	Inhibition of LPS-induced NO production in human BV2 cells preincubated for 2 hrs followed by LPS-stimulation measured after 18 hrs by Griess assay Inhibition of LPS-induced NO production in human BV2 cells preincubated for 2 hrs followed by LPS-stimulation measured after 18 hrs by Griess assay	[PMID: 27525351]
BV-2	IC₅₀	17.6 μM Compound: NG-monomethyl-L-arginine	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 27700070]
BV-2	IC₅₀	21.25 μM Compound: L-NMMA	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay	[PMID: 28165740]
BV-2	IC₅₀	22.1 μM Compound: L-NMMA	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated nitric oxide production by Griess assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated nitric oxide production by Griess assay	[PMID: 28262525]
BV-2	IC₅₀	21.8 μM Compound: L-NMMA	Anti-inflammatory in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pre-incubated before LPS challenge for 24 hrs by Griess reagent based assay Anti-inflammatory in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pre-incubated before LPS challenge for 24 hrs by Griess reagent based assay	[PMID: 28358502]
BV-2	IC₅₀	13.2 μM Compound: L-NMMA	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 30 mins followed by LPS-stimulation after 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 30 mins followed by LPS-stimulation after 24 hrs by Griess assay	[PMID: 28841320]
BV-2	IC₅₀	16.3 μM Compound: NMMA	Antiinflammatory activity in mouse BV2 cells assessed as reduction in LPS-induced nitric oxide production Antiinflammatory activity in mouse BV2 cells assessed as reduction in LPS-induced nitric oxide production	[PMID: 29280630]
BV-2	IC₅₀	21.4 μM Compound: L-NMMA	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs by Griess assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs by Griess assay	[PMID: 30063340]
BV-2	IC₅₀	21.4 μM Compound: L-NMMA	Cytotoxicity against mouse BV2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against mouse BV2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 30232882]
BV-2	IC₅₀	26.58 μM Compound: L-NMMA	Anti-inflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay Anti-inflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay	[PMID: 30472026]
BV-2	IC₅₀	16.05 μM Compound: N-NMMA	Anti-inflammatory activity in mouse BV2 cells assessed as reduction in LPS-induced NO production pre-treated before LPS stimulation for 24 hrs by Griess reagent-based assay Anti-inflammatory activity in mouse BV2 cells assessed as reduction in LPS-induced NO production pre-treated before LPS stimulation for 24 hrs by Griess reagent-based assay	[PMID: 30530196]
BV-2	IC₅₀	17 μM Compound: L-NMMA	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay	[PMID: 31082231]
BV-2	IC₅₀	21.9 μM Compound: L-NMMA	Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition in LPS-induced NO production preincubated for 30 mins followed b LPS addition and measured after 24 hr by griess reagent based assay Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition in LPS-induced NO production preincubated for 30 mins followed b LPS addition and measured after 24 hr by griess reagent based assay	[PMID: 31625742]
BV-2	IC₅₀	28.8 μM Compound: L-NMMA	Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess assay Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess assay	[PMID: 32520551]
BV-2	CC₅₀	>200 μM Compound: L-NMMA	Cytotoxicity against mouse BV-2 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against mouse BV-2 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 34161733]
BV-2	IC₅₀	10 μM Compound: L-NMMA	Anti-neuroinflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs by Griess reagent based assay Anti-neuroinflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs by Griess reagent based assay	[PMID: 34161733]
BV-2	IC₅₀	21.37 μM Compound: L-NMMA	Anti-neuroinflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO production incubated for 48 hrs by Griess reagent based assay Anti-neuroinflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO production incubated for 48 hrs by Griess reagent based assay	[PMID: 34546050]
BV-2	IC₅₀	31.8 μM Compound: L-NMMA	Antineuroinflammatory activity against mouse BV-2 cells assessed as inhibition of LPS-induced NO production by Griess assay Antineuroinflammatory activity against mouse BV-2 cells assessed as inhibition of LPS-induced NO production by Griess assay	[PMID: 34964626]
BV-2	IC₅₀	27.2 μM Compound: L-NMMA	Anti-neuroinflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO production Anti-neuroinflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO production	[PMID: 35263118]
BV-2	IC₅₀	14.77 μM Compound: L-NMMA	Antiinflammatory activity against mouse BV-2 cells assessed as reduction in LPS induced NO production measured for 24 hrs by Griess reagent based analysis Antiinflammatory activity against mouse BV-2 cells assessed as reduction in LPS induced NO production measured for 24 hrs by Griess reagent based analysis	[PMID: 37683361]
DLD-1	IC₅₀	0.3 μM Compound: 1	Ability to inhibit conversion of [3H]L-Arg to [3H]L-citrulline catalyzed by inducible NOS (i NOS) from human DLD-1 cells Ability to inhibit conversion of [3H]L-Arg to [3H]L-citrulline catalyzed by inducible NOS (i NOS) from human DLD-1 cells	[PMID: 11327580]
DLD-1	IC₅₀	170 mM Compound: 1	Inhibitory concentration against nitric oxide synthesis in intact DLD-1 cells Inhibitory concentration against nitric oxide synthesis in intact DLD-1 cells	[PMID: 11327580]
DLD-1	IC₅₀	0.3 μM Compound: 8 (L-NMMA)	Ability to inhibit the conversion of [3H]L-Arg to [3H]L-citrulline catalyzed by i-NOS from human DLD-1 cells Ability to inhibit the conversion of [3H]L-Arg to [3H]L-citrulline catalyzed by i-NOS from human DLD-1 cells	[PMID: 11327581]
DLD-1	IC₅₀	170 μM Compound: 8 (L-NMMA)	Concentration required to inhibit nitric oxide synthesis in DLD-1 cells Concentration required to inhibit nitric oxide synthesis in DLD-1 cells	[PMID: 11327581]
DLD-1	IC₅₀	21 μM Compound: 1	Inhibitory activity against synthesis of inducible nitric oxide synthase by DLD-1 cells Inhibitory activity against synthesis of inducible nitric oxide synthase by DLD-1 cells	[PMID: 12620067]
HUVEC	IC₅₀	0.3 μM Compound: 1	Ability to inhibit conversion of [3H]L-Arg to [3H]L-citrulline catalyzed by endothelial NOS (e NOS) from HUVEC cells Ability to inhibit conversion of [3H]L-Arg to [3H]L-citrulline catalyzed by endothelial NOS (e NOS) from HUVEC cells	[PMID: 11327580]
HUVEC	IC₅₀	0.3 μM Compound: 8 (L-NMMA)	Ability to inhibit the conversion of [3H]L-Arg to [3H]L-citrulline catalyzed by e-NOS from HUVEC cells Ability to inhibit the conversion of [3H]L-Arg to [3H]L-citrulline catalyzed by e-NOS from HUVEC cells	[PMID: 11327581]
J774	IC₅₀	26 μM Compound: L-NMMA	Inhibitory activity against nitric oxide production in lipopolysaccharide (LPS)-activated macrophage -like J774.1 cell Inhibitory activity against nitric oxide production in lipopolysaccharide (LPS)-activated macrophage -like J774.1 cell	[PMID: 12467611]
J774.1	IC₅₀	26 μM Compound: L-NMMA	Inhibition of LPS-induced NO production in mouse J774.1 cells after 24 hrs Inhibition of LPS-induced NO production in mouse J774.1 cells after 24 hrs	[PMID: 12608860]
J774.1	IC₅₀	35.7 μM Compound: L-NMMA	Inhibition of LPS-induced NO production in mouse J774.1cells after 24 hrs Inhibition of LPS-induced NO production in mouse J774.1cells after 24 hrs	[PMID: 15104497]
J774.1	IC₅₀	27.1 μM Compound: L-NMMA	Inhibition of LPS-induced NO production in mouse J774.1 cells after 24 hrs by Griess reagent assay Inhibition of LPS-induced NO production in mouse J774.1 cells after 24 hrs by Griess reagent assay	[PMID: 15974608]
J774.1	IC₅₀	27.1 μM Compound: L-NMMA	Cytotoxicity against LPS induced mouse J774.1 cells by MTT assay Cytotoxicity against LPS induced mouse J774.1 cells by MTT assay	[PMID: 18154272]
J774.1	IC₅₀	31.6 μM Compound: L-NMMA	Inhibition of nitric oxide production in LPS induced mouse J774.1 cells Inhibition of nitric oxide production in LPS induced mouse J774.1 cells	[PMID: 18154272]
J774.1	IC₅₀	22 μg/mL Compound: L-NMMA	Antiinflammatory activity in mouse J774.1 cells assessed as inhibition of LPS-induced NO production Antiinflammatory activity in mouse J774.1 cells assessed as inhibition of LPS-induced NO production	[PMID: 20836516]
J774.1	IC₅₀	13.8 μg/mL Compound: L-NMMA	Inhibition of LPS-induced nitric oxide production in mouse J774.1 cells after 24 hrs by griess assay Inhibition of LPS-induced nitric oxide production in mouse J774.1 cells after 24 hrs by griess assay	[PMID: 21428417]
Macrophage	IC₅₀	28 μM Compound: L-NMMA	Inhibition of LPS-induced NO production in ddY mouse macrophages assessed as nitrate accumulation after 20 hrs by Griess reagent method Inhibition of LPS-induced NO production in ddY mouse macrophages assessed as nitrate accumulation after 20 hrs by Griess reagent method	[PMID: 12398545]
Macrophage	IC₅₀	57 μM Compound: L-NMMA	Inhibition of LPS-induced NO production in ddY mouse macrophages after 20 hrs by Griess reagent assay Inhibition of LPS-induced NO production in ddY mouse macrophages after 20 hrs by Griess reagent assay	[PMID: 15270564]
RAW	IC₅₀	22.1 μM Compound: L-NG-monomethyl arginine	Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells pretreated 15 mins before LPS challenge measured after 20 hrs relative to control Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells pretreated 15 mins before LPS challenge measured after 20 hrs relative to control	[PMID: 21978950]
RAW	IC₅₀	19.7 μM Compound: L-NMMA	Inhibition of LPS-induced iNOS activity in mouse RAW 264.7 cells assessed as inhibition of NO production pretreated with compound for 30 mins before LPS challenge after 24 hrs by Griess reagent method Inhibition of LPS-induced iNOS activity in mouse RAW 264.7 cells assessed as inhibition of NO production pretreated with compound for 30 mins before LPS challenge after 24 hrs by Griess reagent method	[PMID: 23142320]
RAW	IC₅₀	25 μM Compound: 2	Inhibition of radiolabeled arginine conversion to citrulline by isomeric form of Inducible nitric oxide synthase from mouse RAW 264.7 cells Inhibition of radiolabeled arginine conversion to citrulline by isomeric form of Inducible nitric oxide synthase from mouse RAW 264.7 cells	[PMID: 9651169]
RAW264.7	IC₅₀	>50 μM Compound: L-NMMA	Cytotoxicity against mouse RAW264.7 cells by MTT assay Cytotoxicity against mouse RAW264.7 cells by MTT assay	[PMID: 16643064]
RAW264.7	IC₅₀	19.2 μM Compound: L-NMMA	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells assessed as nitrite accumulation after 20 hrs Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells assessed as nitrite accumulation after 20 hrs	[PMID: 16643064]
RAW264.7	IC₅₀	>100.8 μM Compound: L-NMMA	Inhibition of LPS-induced NOS activity in mouse RAW264.7 cells Inhibition of LPS-induced NOS activity in mouse RAW264.7 cells	[PMID: 20738102]
RAW264.7	IC₅₀	19.7 μM Compound: L-NMMA	Inhibition of NO production in mouse RAW264.7 cells Inhibition of NO production in mouse RAW264.7 cells	[PMID: 21261296]
RAW264.7	IC₅₀	19.9 μM Compound: 1, L-NMMA	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 20 hrs by Griess reaction Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 20 hrs by Griess reaction	[PMID: 21377876]
RAW264.7	IC₅₀	19.7 μM Compound: L-NMMA	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins before LPS challenge measured after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins before LPS challenge measured after 24 hrs by Griess method	[PMID: 22115839]
RAW264.7	IC₅₀	19.7 μM Compound: L-NMMA	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins measured 24 hrs post LPS challenge by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins measured 24 hrs post LPS challenge by Griess method	[PMID: 22386564]
RAW264.7	IC₅₀	40.4 μM Compound: N-monomethyl-L-arginine	Inhibition of nitric oxide production in LPS-stimulated mouse RAW264.7 cells by Griess reagent assay Inhibition of nitric oxide production in LPS-stimulated mouse RAW264.7 cells by Griess reagent assay	[PMID: 23394284]
RAW264.7	IC₅₀	21.72 μM Compound: L-NMMA	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production incubated for 15 mins prior to LPS challenge measured after 20 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production incubated for 15 mins prior to LPS challenge measured after 20 hrs by Griess assay	[PMID: 24016057]
RAW264.7	IC₅₀	39.2 μM Compound: L-NMMA	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 2 hrs prior to LPS-challenge measured after 24 hrs by Greiss assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 2 hrs prior to LPS-challenge measured after 24 hrs by Greiss assay	[PMID: 25924023]
RAW264.7	IC₅₀	2.3 μM Compound: L-NMMA	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced iNOS activity incubated for 30 mins prior to LPS challenge measured after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced iNOS activity incubated for 30 mins prior to LPS challenge measured after 24 hrs by Griess assay	[PMID: 25975638]
RAW264.7	IC₅₀	>40.5 μM Compound: N-monomethyl-L-arginine	Inhibition of LPS-induced NO release in mouse RAW264.7 cells after 24 hrs by Griess reaction Inhibition of LPS-induced NO release in mouse RAW264.7 cells after 24 hrs by Griess reaction	[PMID: 26052978]
RAW264.7	IC₅₀	25.1 μM Compound: L-NMMA	Inhibition of nitric oxide production in LPS-stimulated mouse RAW264.7 cells preincubated for 15 mins followed by LPS challenge measured after 20 hrs by Griess assay Inhibition of nitric oxide production in LPS-stimulated mouse RAW264.7 cells preincubated for 15 mins followed by LPS challenge measured after 20 hrs by Griess assay	[PMID: 26343828]
RAW264.7	IC₅₀	73.3 μM Compound: L-NMMA	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production compound pretreated for 1 hr followed by addition of 100 ng/ml LPS for 24 hrs by griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production compound pretreated for 1 hr followed by addition of 100 ng/ml LPS for 24 hrs by griess method	[PMID: 26681510]
RAW264.7	IC₅₀	45 μM Compound: L-NMMA	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by Griess assay	[PMID: 26741483]
RAW264.7	IC₅₀	2.69 μM Compound: L-NMMA	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 18 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 18 hrs by Griess assay	[PMID: 26898337]
RAW264.7	IC₅₀	23.5 μM Compound: L-NMMA	Inhibition of lipopolysaccharide-induced nitric oxide production in mouse RAW264.7 cells pre-incubated for 30 mins before LPS stimulation for 20 hrs by Griess reagent based assay Inhibition of lipopolysaccharide-induced nitric oxide production in mouse RAW264.7 cells pre-incubated for 30 mins before LPS stimulation for 20 hrs by Griess reagent based assay	[PMID: 27210437]
RAW264.7	IC₅₀	2.73 μM Compound: L-NMMA	Cytotoxicity against mouse RAW264.7 cells assessed as decrease in cell proliferation rate after 24 hrs by MTS assay Cytotoxicity against mouse RAW264.7 cells assessed as decrease in cell proliferation rate after 24 hrs by MTS assay	[PMID: 27777005]
RAW264.7	IC₅₀	30.92 μM Compound: L-NMMA	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production pretreated for 2 hrs followed by LPS-stimulation measured after 20 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production pretreated for 2 hrs followed by LPS-stimulation measured after 20 hrs by Griess assay	[PMID: 28753309]
RAW264.7	IC₅₀	25.8 μM Compound: L-NMMA	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 18 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 18 hrs by Griess assay	[PMID: 29400471]
RAW264.7	IC₅₀	16.11 μM Compound: L-NMMA	Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production after 18 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production after 18 hrs by Griess assay	[PMID: 29685654]
RAW264.7	IC₅₀	32.9 μM Compound: L-NMMA	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 18 hrs by Griess assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 18 hrs by Griess assay	[PMID: 30296083]
RAW264.7	IC₅₀	27.2 μM Compound: L-NMMA	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs	[PMID: 31710213]
RAW264.7	IC₅₀	33.84 μM Compound: L-NMMA	Anti-inflammatory activity in murine RAW264.7 cells assessed as inhibition of LPS-induced NO production Anti-inflammatory activity in murine RAW264.7 cells assessed as inhibition of LPS-induced NO production	[PMID: 33207281]
RAW264.7	IC₅₀	35.5 μM Compound: L-NMMA	Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay	[PMID: 33939429]
RAW264.7	IC₅₀	44.36 μM Compound: L-NMMA	Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production incubated for 1 hrs followed by LPS stimulation for 18 hrs by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production incubated for 1 hrs followed by LPS stimulation for 18 hrs by Griess reagent based assay	[PMID: 35427124]
RAW264.7	IC₅₀	30.92 μM Compound: L-NMMA	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 18 hrs by Griess assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 18 hrs by Griess assay	[PMID: 37683361]
RAW264.7	IC₅₀	33 μM Compound: L-NMMA	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent based analysis Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent based analysis	[PMID: 38320172]
RAW264.7	IC₅₀	27.84 μM Compound: L-NMMA	Antiinflammatory activity in LPS activated mouse RAW264.7 cells assessed as inhibition of NO production Antiinflammatory activity in LPS activated mouse RAW264.7 cells assessed as inhibition of NO production	[PMID: 38522589]
RAW264.7	IC₅₀	5.24 μg/mL Compound: L-NMMA	Antiinflammatory activity in LPS activated mouse RAW264.7 cells assessed as inhibition of NO production Antiinflammatory activity in LPS activated mouse RAW264.7 cells assessed as inhibition of NO production	[PMID: 38522589]
RAW264.7	IC₅₀	31.74 μM Compound: L-NMMA	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs	[PMID: 38959374]
Sf9	IC₅₀	0.65 μM Compound: L-NMMA	Inhibition of human eNOS expressed in Sf9 cells assessed as reduction in conversion of [3H]L-arginine to [3H]L-citrulline preincubated for 15 mins by radiometric method Inhibition of human eNOS expressed in Sf9 cells assessed as reduction in conversion of [3H]L-arginine to [3H]L-citrulline preincubated for 15 mins by radiometric method	[PMID: 22335555]
Sf9	IC₅₀	0.95 μM Compound: L-NMMA	Inhibition of human nNOS expressed in Sf9 cells assessed as reduction in conversion of [3H]L-arginine to [3H]L-citrulline preincubated for 15 mins by radiometric method Inhibition of human nNOS expressed in Sf9 cells assessed as reduction in conversion of [3H]L-arginine to [3H]L-citrulline preincubated for 15 mins by radiometric method	[PMID: 22335555]
Sf9	IC₅₀	1.8 μM Compound: L-NMMA	Inhibition of human recombinant iNOS expressed in Sf9 cells assessed as reduction in conversion of [3H]L-arginine to [3H]L-citrulline preincubated for 15 mins by radiometric method Inhibition of human recombinant iNOS expressed in Sf9 cells assessed as reduction in conversion of [3H]L-arginine to [3H]L-citrulline preincubated for 15 mins by radiometric method	[PMID: 22335555]

In Vivo

L-NMMA (50 µg; i.t.; single administration) significantly alleviates bone cancer-induced mechanical allodynia and thermal hyperalgesia in mice at 2 and 12 h post-treatment^[1].
L-NMMA (20 nmol; intravitreal injection; once every other day; 2 to 4 weeks) alleviates choroidal fibrosis and delays myopia progression by inhibiting the NO signaling pathway in lens-induced myopic guinea pigs^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C3H/HeJ (male, 4-6 weeks old, 20-22 g, intramedullary inoculation of NCTC 2472 osteosarcoma cells)^[1]
Dosage:

50 µg
Administration:

i.t.; single administration
Result:

Increased paw withdrawal mechanical threshold to 0.90 g at 2 h and 0.63 g at 12 h compared to 0.40 g in vehicle-treated tumor mice.
Increased paw withdrawal thermal latency to 16.2 sec at 2 h and 12.7 sec at 12 h compared to 10.1 sec in vehicle-treated tumor mice.
Lost analgesic effect at 24 h post-administration.

Animal Model:

British short-haired tricolor guinea pigs (2-week-old, 110-130 g, lens-induced myopia model)^[2]
Dosage:

20 nmol
Administration:

intravitreal injection; once every other day; 2 and 4 weeks
Result:

Increased refraction significantly after 2 and 4 weeks compared to the lens-induced myopia group.
Reduced the D-value of axial length between the myopic eye and control eye significantly after 2 and 4 weeks compared to the lens-induced myopia group.
Increased choroidal thickness to 80.62 μm at 4 weeks compared to 63.54 μm in the lens-induced myopia group.
Reduced degradation of choroidal pigment particles and narrowed particle gaps compared to the lens-induced myopia group.
Produced denser, more orderly choroidal tissue structure compared to the lens-induced myopia group.
Reduced choroidal fibrosis compared to the lens-induced myopia group.
Lowered gene expression levels of NOS1, NOS3, TGF-β1, COL I, and α-SMA significantly after 2 and 4 weeks compared to the lens-induced myopia group.
Lowered protein levels of NOS1, NOS3, TGF-β1, COL I, and α-SMA significantly after 2 and 4 weeks compared to the lens-induced myopia group.
Reduced expression of COL I, α-SMA, NOS1, NOS3, and TGF-β1 in choroidal tissues compared to the lens-induced myopia group.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 17035-90-4
Appearance Solid
Molecular Weight 188.23
Formula C₇H₁₆N₄O₂
Color Off-white to light yellow
SMILES

OC([C@@H](N)CCCNC(NC)=N)=O
Synonyms

Tilarginine; Methylarginine
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (11)

All Bio/Physico-chemical AssayCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Cell Metab

Lighting up arginine metabolism reveals its functional diversity in physiology and pathology. [Abstract]

2025 Jan 7;37(1):291-304.e9. PMID: 39413790
Nat Immunol

Ammonia detoxification promotes CD8+ T cell memory development by urea and citrulline cycles. [Abstract]

2023 Jan;24(1):162-173. PMID: 36471170

L-NMMA purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2023 Jan;24(1):162-173. [Abstract]

L-NMMA acetate (200 μM; 48 h) led to elevating ammonia and inhibiting CD8⁺ T_M cell induction, in parallel with the inhibition of NO production.

L-NMMA purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2023 Jan;24(1):162-173. [Abstract]

L-NMMA acetate (100 μM; 48 h) led to the accumulation of m + 1 arginine and a slowed nitrogen flow in CD8⁺ T_M cells.

L-NMMA purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2023 Jan;24(1):162-173. [Abstract]

L-NMMA acetate (100 μM; 48 h) blocked formation of CD8⁺ T_M cells.

L-NMMA purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2023 Jan;24(1):162-173. [Abstract]

CD8⁺ T_M cells were treated with L-NMMA acetate (100 μM; 48 h) and the level of urea was analyzed.

L-NMMA purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2023 Jan;24(1):162-173. [Abstract]

IL-15-derived CD8⁺ T_M cells were treated with L-NMMA acetate (100 μM; 48 h), then were cultured with [U4] ¹⁵N-arginine for 6 hours and LC-MS/MS analysis was performed for m + 2, m + 3 citrulline, m + 2 ornithine and m + 2 urea.
Nat Commun

An infection-induced RhoB-Beclin 1-Hsp90 complex enhances clearance of uropathogenic Escherichia coli. [Abstract]

2021 May 10;12(1):2587. PMID: 33972537
Cell Mol Gastroenterol Hepatol

Citrulline inhibits Clostridioides difficile infection with anti-inflammatory effects. [Abstract]

2025 Feb 7:101474. PMID: 39923847
Cell Mol Gastroenterol Hepatol

Fibrinogen/AKT/Microfilament Axis Promotes Colitis by Enhancing Vascular Permeability. [Abstract]

2021;11(3):683-696. PMID: 33075564
Life Sci

Identification and regulation of a novel leptin receptor-linked enhancer during zebrafish ventricle regeneration. [Abstract]

2025 Jan 24:123415. PMID: 39864617
EMBO Rep

Tudor-based proteomic strategy pan-specifically enriches and identifies protein arginine methylation. [Abstract]

2025 Oct 20. PMID: 41116072
Front Cell Dev Biol

mTOR Signaling Regulates the Development and Therapeutic Efficacy of PMN-MDSCs in Acute GVHD. [Abstract]

2021 Dec 23;9:741911. PMID: 35004668
FASEB J

Spatial Metabolism of Primary Limited Cutaneous Amyloidosis Based on Mass Spectrometry Imaging. [Abstract]

2025 Sep 30;39(18):e71057. PMID: 40955599
Eur J Immunol

Fibroblast transdifferentiation promotes conversion of M1 macrophages and replenishment of cardiac resident macrophages following cardiac injury in mice. [Abstract]

2020 Jun;50(6):795-808. PMID: 32068249
Theriogenology

Nitric oxide regulates spindle dynamics to modulate the maturation of goat oocytes. [Abstract]

2025 May 29:245:117517. PMID: 40460471

Solvent & Solubility

In Vitro:

H₂O : 100 mg/mL (531.26 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.3126 mL

26.5632 mL

53.1265 mL

5 mM

1.0625 mL

5.3126 mL

10.6253 mL

10 mM

0.5313 mL

2.6563 mL

5.3126 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Yang Y, et al. Role of nitric oxide synthase in the development of bone cancer pain and effect of L-NMMA. Mol Med Rep. 2016;13(2):1220-1226. [Content Brief]

[2]. Li T, et al. Suppressive effect of nitric oxide synthase (NOS) inhibitor L-NMMA acetate on choroidal fibrosis in experimental myopic guinea pigs through the nitric oxide signaling pathway. Eur J Pharmacol. 2023;960:176111. [Content Brief]

[3]. Babbedge RC, et al. Anti-nociceptive activity of nitric oxide synthase inhibitors in the mouse: dissociation between the effect of L-NAME and L-NMMA. J Pharm Pharmacol. 1993;45(1):77-79. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	5.3126 mL	26.5632 mL	53.1265 mL	132.8162 mL
	5 mM	1.0625 mL	5.3126 mL	10.6253 mL	26.5632 mL
	10 mM	0.5313 mL	2.6563 mL	5.3126 mL	13.2816 mL
	15 mM	0.3542 mL	1.7709 mL	3.5418 mL	8.8544 mL
	20 mM	0.2656 mL	1.3282 mL	2.6563 mL	6.6408 mL
	25 mM	0.2125 mL	1.0625 mL	2.1251 mL	5.3126 mL
	30 mM	0.1771 mL	0.8854 mL	1.7709 mL	4.4272 mL
	40 mM	0.1328 mL	0.6641 mL	1.3282 mL	3.3204 mL
	50 mM	0.1063 mL	0.5313 mL	1.0625 mL	2.6563 mL
	60 mM	0.0885 mL	0.4427 mL	0.8854 mL	2.2136 mL
	80 mM	0.0664 mL	0.3320 mL	0.6641 mL	1.6602 mL
	100 mM	0.0531 mL	0.2656 mL	0.5313 mL	1.3282 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

L-NMMA

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Neuroprotective Compound Library

Angiogenesis-Related Compound Library

Rare Diseases Drug Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Mouse Metabolite Compound Library

Chinese Baijiu Compound Library

Publications Citing Use of MedChemExpress (MCE) L-NMMA

All NO Synthase Isoforms

Biological Activity

Chemical Information

Publications (11)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

L-NMMA

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Neuroprotective Compound Library

Angiogenesis-Related Compound Library

Rare Diseases Drug Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Mouse Metabolite Compound Library

Chinese Baijiu Compound Library

Publications Citing Use of MedChemExpress (MCE) L-NMMA

All NO Synthase Isoforms

Biological Activity

Chemical Information

Publications (11)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

L-NMMA Related Classifications

HY-18732 Related Classifications